Multiple Sclerosis. Multiple Sclerosis
Conditions
Interventions
Intervention 1: The intervention group will receive 1000mg/day (two 500 mg tablets/day) of a-L-Guluronic acid orally for 24 weeks. The a-L-Guluronic acid produced from the decomposition of Alginate po
Treatment - Drugs
25 pationts as control group use only their conventional drug(Interferon beta).
The intervention group will receive 1000mg/day (two 500 mg tablets/day) of a-L-Guluronic acid orally for 24 weeks. The a-L-Guluronic acid produced from the decomposition of Alginate powder (a safe, na
Sponsors
Vice chancellor for Research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria: diagnosed with multiple sclerosis who were injecting different forms interferon,beta (interferon beta, 1a, interferon beta, 1b) at least 6 months before the trial. Also, the patients have been chosen by neurologist among active patients on the basis of disease activity who have had at least one relapsing period during 6month or have active lesions in their MRI imaging. Written informed consent will be obtained; Exclusion Criteria: History of fever and Infectious diseases, Positive pregnancy test or Lactation, Other collagen vascular diseases, Other autoimmune diseases, Malignancies, Patients have enrolled another clinical trial study within last 4 weeks, Other concomitant diseases (Hepatic, renal, hematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological or cerebral disease).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Active lesion in MRI imaging. Timepoint: At baseline and after 24 weeks of treatment. Method of measurement: imaging by MRI method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum level of AST. Timepoint: At baseline and after 24 weeks of treatment. Method of measurement: Biochemical measurements.;Serum level of uric acid. Timepoint: At baseline and after 24 weeks of treatment. Method of measurement: Biochemical measurements.;Serum level of ALT. Timepoint: At baseline and after 24 weeks of treatment. Method of measurement: Biochemical measurements.;Serum level of BUN. Timepoint: At baseline and after 24 weeks of treatment. Method of measurement: Biochemical measurements. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Abbas Mirshafiey
Department of pathobiology, School of Public Health, Tehran University of Medical Sciences
Outcome results
None listed